Research Article
The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
| Characteristic | 1st TKIs/2nd chemotherapy | 1st chemotherapy/2nd TKIs | value | () | () |
| Age, yr, median (IQR) | 59 (52–69) | 58 (52–64) | 0.15 | Female, (%) | 30 (54.5%) | 27 (48.2%) | 0.5 | Smoking, (%) | 25 (45.5%) | 17 (30.4%) | 0.1 | Performance status at beginning of 1st-line treatment | | | | 0-1 | 42 (76.4%) | 47 (83.9%) | 0.32 | 2 | 9 (16.4%) | 8 (14.3%) | 0.76 | >2 | 4 (7.3%) | 1 (1.8%) | 0.16 | EGFR mutation status | | | | 19Del | 21 (38.1%) | 23 (41.0%) | 0.74 | L858R | 32 (58.2%) | 31 (55.4%) | Others | 2 (3.7%) | 2 (3.6%) | Progression site from each 1st-line treatment | | | | Primary lung | 17 (30.9%) | 19 (33.9%) | 0.73 | Lung to lung metastasis | 10 (18.2%) | 9 (16.1%) | 0.77 | Bone | 6 (10.9%) | 9 (16.1%) | 0.43 | Pleural effusion | 6 (10.9%) | 7 (12.4%) | 0.79 | CNS | 9 (16.4%) | 5 (8.9%) | 0.52 | Liver | 3 (5.5%) | 2 (3.6%) | 0.63 | Adrenal gland | 2 (3.6%) | 3 (5.4%) | 0.66 | Others | 2 (3.6%) | 2 (3.6%) | 0.99 | Performance status at beginning of 2nd line treatment | | | | 0-1 | 29 (52.7%) | 38 (67.9%) | 0.10 | 2 | 21 (38.2%) | 15 (26.8%) | 0.20 | >2 | 5 (9.1%) | 3 (5.3%) | 0.45 |
|
|
IQR: interquartile range; CNS: central nervous system.
|